-
Abbisko Therapeutics’ Pimicotinib Earns Orphan Drug Designation from EMA for TGCT Treatment
•
Abbisko Therapeutics Co., Ltd (HKG: 2256), a Shanghai-based biotechnology company, has announced that it has received orphan drug designation (ODD) from the European Medicines Agency (EMA) for its proprietary colony stimulating factor-1 receptor (CSF-1R) inhibitor, pimicotinib (ABSK021). The drug is under development for the treatment of inoperable tenosynovial giant cell…
-
Gilead’s Descovy Receives Additional Indication Approval from China’s NMPA for HIV-1 PrEP
•
Gilead Sciences, Inc. (NASDAQ: GILD), a major player in the pharmaceutical industry in the U.S., has announced that it has received an additional indication approval from China’s National Medical Products Administration (NMPA) for its anti-viral drug Descovy (emtricitabine, tenofovir alafenamide fumarate). The NMPA has granted approval for the use of…
-
Bebig Medical Group Secures Over USD 14 Million in Series B Financing to Boost Radiotherapy Technology
•
Bebig Medical Group, a Germany-based provider of high-quality radiation therapy products with a presence in China and the United States, has reportedly secured over RMB 100 million (USD 14 million) in a Series B financing round. The sole investor in this round was Cathay Capital. The funds raised are intended…
-
Chengdu Kanghua Strikes Licensing Deal with HilleVax for Recombinant Norovirus Vaccine
•
Chengdu Kanghua Biological Products Co., Ltd (SHE: 300841), a biopharmaceutical company based in China, has entered into a licensing agreement with HilleVax Inc. (NASDAQ: HLVX), granting the US firm exclusive rights to develop, manufacture, and commercialize Kanghua’s recombinant hexavalent norovirus vaccine on a worldwide basis, excluding the Greater China region…
-
CSBIO’s Multi-Kinase Inhibitor CSCJC3456 Gets Green Light for Clinical Trials in Advanced Solid Tumors
•
Hebei Changshan Biochemical Pharmaceutical Co., Ltd (CSBIO; SHE: 300255), a Chinese pharmaceutical company, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its small-molecule multi-kinase inhibitor, CSCJC3456. This molecule is now set to be evaluated in the context of general advanced malignant…
-
Triastek Partners with Kangerjia to Develop 3D-Printed Modified Drugs for Sleep Disorders
•
Triastek Inc., a China-based pharmaceutical-focused 3D printing company, has entered into a partnership with fellow Chinese firm Nanjing Kangerjia Medical Technology Co., Ltd to collaboratively develop modified drugs aimed at treating sleep disorders. This strategic alliance combines Triastek’s expertise in 3D printing technology with Kangerjia’s commercialization experience in the field…
-
Aidea Pharmaceutical Receives NMPA Approval to Clinically Test HIV-1 Treatment ACC017
•
Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a pharmaceutical company based in China, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its Category 1 drug, ACC017. This molecule is now cleared for assessment as a potential treatment for HIV-1 infection when…
-
WuXi Biologics Expands Manufacturing Capacity to 36,000 Liters at Worcester Facility
•
WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) based in China, has announced a significant expansion of its manufacturing capacity at the facility located in Worcester, Massachusetts. The total manufacturing capacity at the site is set to increase to 36,000 liters, marking a substantial upgrade…
